More and more evidence indicates that long non-coding RNAs (lncRNAs), as a kind of non-coding endogenous single-stranded RNA, play an essential role as oncogenes or tumour suppressors in the occurrence and development of human cancers. The tumour protein P73 antisense RNA 1 (TP73-AS1) was initially found to be down-regulated in oligodendroglioma and may act as a non-protein-encoding RNA. Since its discovery, TP73-AS1 has been identified as a carcinogenic regulator of many malignancies. At the same time, the high expression of TP73-AS1 is related to the clinicopathological features of patients with cancer. It also regulates cell proliferation, anti-apoptosis, invasion and metastasis through a variety of potential mechanisms, suggesting that it may be a promising biomarker and therapeutic target for cancer. In this review, we summarize the biological functions, mechanisms, and potential clinical implications of TP73-AS1 dysregulation in tumourigenesis and progression.

中文翻译：

---

癌症中的长非编码RNA TP73-AS1。

越来越多的证据表明，长的非编码RNA（lncRNA）作为一种非编码内源性单链RNA，在人类癌症的发生和发展中作为癌基因或肿瘤抑制因子发挥着至关重要的作用。最初发现肿瘤蛋白P73反义RNA 1（TP73-AS1）在少突胶质细胞瘤中被下调，并且可能充当非蛋白编码RNA。自发现以来，TP73-AS1被确定为许多恶性肿瘤的致癌调节剂。同时，TP73-AS1的高表达与癌症患者的临床病理特征有关。它还通过多种潜在机制调节细胞增殖，抗凋亡，侵袭和转移，表明它可能是癌症的有前途的生物标志物和治疗靶标。在这篇评论中